Claims for Patent: 12,384,758

Summary for Patent: 12,384,758

Title:	Crystalline form of LNP023
Abstract:	Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
Inventor(s):	Zichen JIA, Philipp Lustenberger, Marie Meyer, Massimo Moratto
Assignee:	Novartis AG
Application Number:	US18/168,711
Patent Claims:	1. A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of a crystalline hydrate form of a compound having Formula (A) characterized by having a powder X-ray diffractogram comprising peaks at 2-Theta angles of (4.6±0.2)°, (9.2±0.2°) and (19.1±0.2)°, when measured at a temperature in the range of from 20 to 30° C. with Cu-Kalpha1,2 radiation having a wavelength of 0.15419 nm, wherein the disease or disorder is selected from C3G (C3 glomerulopathy), IgAN (immunoglobuline A nephropathy), MN (membranous nephropathy), HUS (E. coli induced hemolytic uremic syndrome), age-related macular degeneration, geographic atrophy, Guillain Barre Syndrome, traumatic brain injury, myocarditis, post-ischemic reperfusion conditions, myocardial infarction, systemic lupus erythematosus (SLE) nephritis, myasthenia gravis, antiphospholipid syndrome, anca vasculitis, cryoglobulinemia, atypical hemolytic uremic syndrome (aHUS). 2. The method of claim 1, wherein the disease or disorder is selected from C3G (C3 glomerulopathy), IgAN (immunoglobuline A nephropathy), HUS (E. coli induced hemolytic uremic syndrome), age-related macular degeneration, geographic atrophy, myasthenia gravis, anca vasculitis, and aHUS (atypical hemolytic uremic syndrome). 3. The method of claim 1, wherein the crystalline hydrate form is characterized by having a powder X-ray diffractogram comprising one or two peaks at 2-Theta angles of (6.8±0.2°) or (24.6±0.2)°, when measured at a temperature in the range of from 20 to 30° C. with Cu-Kalpha1,2 radiation having a wavelength of 0.15419 nm. 4. The method of claim 1, wherein the hydrate form is a monohydrate. 5. The method of claim 1, wherein the compound having Formula (A) is administered to the subject in a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient. 6. The method of claim 1, comprising administering to the subject the compound having Formula (A) at a daily dose of up to about 400 mg, calculated as an anhydrous free base of the compound having Formula (A), wherein the disease or disorder is selected from C3G (C3 glomerulopathy) and IgAN (immunoglobuline A nephropathy). 7. The method of claim 6, comprising administering to the subject the compound having Formula (A) twice daily. 8. The method of claim 7, comprising administering to the subject the compound having Formula (A) twice daily at 200 mg, calculated as an anhydrous free base of the compound having Formula (A). 9. The method of claim 1, wherein the compound having Formula (A) is administered to the subject in a pharmaceutical composition that is a capsule.